CoChat

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Open access
Vojnic, Morana, Kubota, Daisuke, Kurzatkowski, Christopher, Offin, Michael, Suzawa, Ken, Benayed, Ryma, Schoenfeld, Adam J., Plodkowski, Andrew J., Poirier, John T., Rudin, Charles M., Kris, Mark G., Rosen, Neal X., Yu, Helena A., Riely, Gregory J., Arcila, Maria E., Somwar, Romel, Ladanyi, Marc · 2019 · Journal of Thoracic Oncology
Cited by 104

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Introduction: Multiple genetic mechanisms have been identified in EGFR‐mutant lung cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs), but many cases still lack a known mechanism. Methods: To identify novel mechanisms of AR, we performed targeted large panel sequencing of samples from 374 consecutive patients with metastatic EGFR‐mutant lung cancer, including 174 post‐TKI samples, of which 38 also had a matched pre‐TKI sample. Alterations hypothesized to confer AR were introduced into drug‐sensitive EGFR‐mutant lung cancer cell lines (H1975, HCC827, and PC9) by using clustered regularly interspaced short palindromic repeats/Cas9 genome editing. MSK‐LX138cl, a cell line with EGFR exon 19 deletion (ex19del) and praja ring finger ubiquitin ligase 2 gene (PJA2)/BRAF fusion, was generated from an EGFR TKI–resistant patient sample. Results: We identified four patients (2.3%) with a BRAF fusion (three with acylglycerol kinase gene (AGK)/BRAF and one with PJA2/BRAF) in samples obtained at AR to EGFR TKI therapy (two posterlotinib samples and two posterlotinib and postosimertinib samples). Pre‐TKI samples were available for two of four patients and both were negative for BRAF fusion. Induction of AGK/BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cells increased phosphorylation of BRAF, MEK1/2, ERK1/2, and signal transducer and activator of transcription 3 and conferred resistance to growth inhibition by osimertinib. MEK inhibition with trametinib synergized with osimertinib to block growth. Alternately, a pan‐RAF inhibitor as a single agent blocked growth of all cell lines with mutant EGFR and BRAF fusion. Conclusion: BRAF fusion is a mechanism of AR to EGFR TKI therapy in approximately 2% of patients. Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or BRAF (with a pan‐RAF inhibitor) are potential therapeutic strategies that should be explored.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.12.038

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Vojnic, M., Kubota, D., Kurzatkowski, C., Offin, M., Suzawa, K., Benayed, R., Schoenfeld, A. J., Plodkowski, A. J., Poirier, J. T., Rudin, C. M., Kris, M. G., Rosen, N. X., Yu, H. A., Riely, G. J., Arcila, M. E., Somwar, R., & Ladanyi, M.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-05
Volume
14
Issue
5
Pages
802-815
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2919959132
Cited by
104
References
12
FWCI
10.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.